Clinical Cancer Research
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
Abstract Purpose: Advanced sarcomas lack effective maintenance therapies after first-line chemotherapy. We present long-term phase I results evaluating multiantigen stimulated cell therapy I (MASCT-I), a novel immunotherapy integrating dendritic cell vaccination with adoptive T-cell transfer, as maintenance treatment (NCT03034304). Patients and Methods: Thirty-one patients with disease control after chemotherapy received MASCT-I alone (n = 17) or with ifosfamide (n = 14). The primary endpoint was safety. Secondary …